Status:
RECRUITING
Neurobehavioral Correlates of Caffeine on Anxiety, Avoidance and Interoception in Healthy Individuals and Panic Disorder.
Lead Sponsor:
Uppsala University
Conditions:
Panic Disorder
Healthy
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The current study is a placebo-controlled, double-blind, randomized controlled study using a cross-over design, including Healthy Controls (HC) and participants with Panic Disorder (PD). The primary ...
Detailed Description
Given the novelty of the intended study and the lack of previous neuroimaging and emotion-related behavioral studies on caffeine effects in HCs and PD, analyses will be exploratory without directed hy...
Eligibility Criteria
Inclusion
- Panic Disorder group (PD): Primary diagnosis of Panic Disorder.
- Healthy control group (HCs): No current or history of psychiatric disorders.
- All participants (PD and HCs): Weekly caffeine consumption ≤ 300 mg.
Exclusion
- Weekly caffeine consumption ≥ 300 mg.
- Thoracic or head surgery, or any other surgery or metallic implanted devices not compatible with the safety standards for 7T MR scanner.
- History of severe psychiatric disorder (e.g., schizophrenia).
- Somatic or neurological conditions (e.g., hypertension and heart condition).
- Ongoing treatment with psychotropic medication or treatment with psychotropic medication which has been discontinued within 2 months.
- Other ongoing treatments that may confound the results.
- Current drug or alcohol abuse/dependency.
- Habitual nicotine use.
- Uncorrected visual or hearing impairment.
- Pregnancy.
Key Trial Info
Start Date :
October 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06145490
Start Date
October 29 2024
End Date
September 1 2025
Last Update
November 1 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National 7T Facility - Lunds universitet
Lund, Sweden
2
Uppsala University, Department of Medical Sciences, Psychiatry
Uppsala, Sweden, 75185